Real-World Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from Longitudinal Analyses in 6- and 12-month Cohorts From the PPD CorEvitas Atopic Dermatitis Registry
Bibliographic record
Abstract
Introduction: Clinical trials previously established the short and long-term efficacy and safety of upadacitinib (UPA) for the treatment of atopic dermatitis (AD). Here we report 12-month real-world effectiveness of UPA in adults from the PPD™ CorEvitas™ AD Registry. Materials and Methods The PPD™ CorEvitas™ AD Registry is a prospective, non-interventional registry of adults with AD in the US and Canada. Participants in this analysis were enrolled through May 30, 2025, with data available for the baseline and 12-month follow up visit, at which they were receiving UPA treatment. We report on achievement of validated Investigators Global Assessment Scale for AD of “clear” or “almost clear” (vIGA-AD 0/1) for participants with a score ≥2 at baseline, improvement of ≥90%/100% from baseline in Eczema Area and Severity (EASI 90/100), Peak Pruritus Numeric Rating Scale PP-NRS score of 0 or 1 for participants with a baseline score ≥1 (PP-NRS 0/1; little-to-no itch), Dermatology Life Quality Index score of 0 or 1 for participants with a baseline score ≥1 (DLQI 0/1; no effect on quality of life [QoL]), and simultaneous achievement of EASI 90 + PP-NRS 0/1. Proportions are reported as observed with no imputation. Safety was not assessed in this analysis. Results A total of 189 participants were included in the 12-month analysis (mean age at baseline 47.2 years, 53.4% female, and 39.7% had prior biologic experience). Most participants (65.5%, 114/174) achieved vIGA-AD 0/1, and EASI 90 (62.2%; 112/180); nearly half (48.9%; 88/180) achieved EASI 100. Many participants reported little-to-no itch (41.4%; 70/169) and no effect of AD on QoL (44.6%; 78/175). Over one-third (37.9%; 61/161) of participants achieved simultaneous EASI 90 + PP-NRS 0/1. These results are comparable with the results of a separate 6-month visit cohort analysis. Conclusion In a real-world setting, many patients with 12 months of treatment with upadacitinib reported little-to-no itch, clear or almost clear skin, including simultaneous achievement of skin clearance and itch relief, and no impact of AD on their QoL. The comparable achievement of optimal treatment targets at 6- and 12-months underscore UPA long-term consistency and effectiveness in AD treatment.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".